These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
752 related articles for article (PubMed ID: 31090071)
1. Effect of FGF/FGFR pathway blocking on lung adenocarcinoma and its cancer-associated fibroblasts. Hegab AE; Ozaki M; Kameyama N; Gao J; Kagawa S; Yasuda H; Soejima K; Yin Y; Guzy RD; Nakamura Y; Ornitz DM; Betsuyaku T J Pathol; 2019 Oct; 249(2):193-205. PubMed ID: 31090071 [TBL] [Abstract][Full Text] [Related]
2. Characterization of the cell of origin and propagation potential of the fibroblast growth factor 9-induced mouse model of lung adenocarcinoma. Arai D; Hegab AE; Soejima K; Kuroda A; Ishioka K; Yasuda H; Naoki K; Shizuko K; Hamamoto J; Yin Y; Ornitz DM; Betsuyaku T J Pathol; 2015 Mar; 235(4):593-605. PubMed ID: 25413587 [TBL] [Abstract][Full Text] [Related]
3. Interaction between the estrogen receptor and fibroblast growth factor receptor pathways in non-small cell lung cancer. Siegfried JM; Farooqui M; Rothenberger NJ; Dacic S; Stabile LP Oncotarget; 2017 Apr; 8(15):24063-24076. PubMed ID: 28445992 [TBL] [Abstract][Full Text] [Related]
4. Tumor associated macrophages support the growth of FGF9-induced lung adenocarcinoma by multiple mechanisms. Hegab AE; Ozaki M; Kagawa S; Hamamoto J; Yasuda H; Naoki K; Soejima K; Yin Y; Kinoshita T; Yaguchi T; Kawakami Y; Ornitz DM; Betsuyaku T Lung Cancer; 2018 May; 119():25-35. PubMed ID: 29656749 [TBL] [Abstract][Full Text] [Related]
5. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression. Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034 [TBL] [Abstract][Full Text] [Related]
6. A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma. Wang L; Šuštić T; Leite de Oliveira R; Lieftink C; Halonen P; van de Ven M; Beijersbergen RL; van den Heuvel MM; Bernards R; van der Heijden MS Eur Urol; 2017 Jun; 71(6):858-862. PubMed ID: 28108151 [TBL] [Abstract][Full Text] [Related]
7. Fibroblast growth factor-2, derived from cancer-associated fibroblasts, stimulates growth and progression of human breast cancer cells via FGFR1 signaling. Suh J; Kim DH; Lee YH; Jang JH; Surh YJ Mol Carcinog; 2020 Sep; 59(9):1028-1040. PubMed ID: 32557854 [TBL] [Abstract][Full Text] [Related]
8. Upregulation of Fibroblast Growth Factors Caused by Heart and Neural Crest Derivatives Expressed 2 Suppression in Endometriotic Cells: A Possible Therapeutic Target in Endometriosis. Kato N; Iwase A; Ishida C; Nagai T; Mori M; Bayasula ; Nakamura T; Osuka S; Ganiyeva U; Qin Y; Miki R; Kikkawa F Reprod Sci; 2019 Jul; 26(7):979-987. PubMed ID: 30270745 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of the FGF/FGFR System Induces Apoptosis in Lung Cancer Cells via c-Myc Downregulation and Oxidative Stress. Giacomini A; Taranto S; Rezzola S; Matarazzo S; Grillo E; Bugatti M; Scotuzzi A; Guerra J; Di Trani M; Presta M; Ronca R Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33317057 [TBL] [Abstract][Full Text] [Related]
10. Fibroblast growth factor-2-mediated FGFR/Erk signaling supports maintenance of cancer stem-like cells in esophageal squamous cell carcinoma. Maehara O; Suda G; Natsuizaka M; Ohnishi S; Komatsu Y; Sato F; Nakai M; Sho T; Morikawa K; Ogawa K; Shimazaki T; Kimura M; Asano A; Fujimoto Y; Ohashi S; Kagawa S; Kinugasa H; Naganuma S; Whelan KA; Nakagawa H; Nakagawa K; Takeda H; Sakamoto N Carcinogenesis; 2017 Oct; 38(11):1073-1083. PubMed ID: 28927233 [TBL] [Abstract][Full Text] [Related]
11. Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors. Feng S; Shao L; Castro P; Coleman I; Nelson PS; Smith PD; Davies BR; Ittmann M Oncotarget; 2017 Jan; 8(4):6179-6192. PubMed ID: 28008155 [TBL] [Abstract][Full Text] [Related]
12. Protein Kinase Cι and Wnt/β-Catenin Signaling: Alternative Pathways to Kras/Trp53-Driven Lung Adenocarcinoma. Yin N; Liu Y; Khoor A; Wang X; Thompson EA; Leitges M; Justilien V; Weems C; Murray NR; Fields AP Cancer Cell; 2019 Aug; 36(2):156-167.e7. PubMed ID: 31378680 [TBL] [Abstract][Full Text] [Related]
13. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Gavine PR; Mooney L; Kilgour E; Thomas AP; Al-Kadhimi K; Beck S; Rooney C; Coleman T; Baker D; Mellor MJ; Brooks AN; Klinowska T Cancer Res; 2012 Apr; 72(8):2045-56. PubMed ID: 22369928 [TBL] [Abstract][Full Text] [Related]
14. Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance. Chell V; Balmanno K; Little AS; Wilson M; Andrews S; Blockley L; Hampson M; Gavine PR; Cook SJ Oncogene; 2013 Jun; 32(25):3059-70. PubMed ID: 22869148 [TBL] [Abstract][Full Text] [Related]
15. Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy. Biello F; Burrafato G; Rijavec E; Genova C; Barletta G; Truini A; Coco S; Bello MG; Alama A; Boccardo F; Grossi F Anticancer Agents Med Chem; 2016; 16(9):1142-54. PubMed ID: 26845137 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of fibroblast growth factor receptor with AZD4547 mitigates juvenile nasopharyngeal angiofibroma. Le T; New J; Jones JW; Usman S; Yalamanchali S; Tawfik O; Hoover L; Bruegger DE; Thomas SM Int Forum Allergy Rhinol; 2017 Oct; 7(10):973-979. PubMed ID: 28707818 [TBL] [Abstract][Full Text] [Related]
17. Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Giri D; Ropiquet F; Ittmann M Clin Cancer Res; 1999 May; 5(5):1063-71. PubMed ID: 10353739 [TBL] [Abstract][Full Text] [Related]
18. Upregulation of FGF9 and NOVA1 in cancer-associated fibroblasts promotes cell proliferation, invasion and migration of triple negative breast cancer. Zhang B; Liu Y; Yu J; Lin X Drug Dev Res; 2024 May; 85(3):e22185. PubMed ID: 38657094 [TBL] [Abstract][Full Text] [Related]
19. Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547. Delpuech O; Rooney C; Mooney L; Baker D; Shaw R; Dymond M; Wang D; Zhang P; Cross S; Veldman-Jones M; Wilson J; Davies BR; Dry JR; Kilgour E; Smith PD Mol Cancer Ther; 2016 Nov; 15(11):2802-2813. PubMed ID: 27550940 [TBL] [Abstract][Full Text] [Related]
20. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer. Takai K; Le A; Weaver VM; Werb Z Oncotarget; 2016 Dec; 7(50):82889-82901. PubMed ID: 27756881 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]